研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

β-arrestin2:炎症免疫疾病的新兴参与者和潜在治疗靶点。

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases.

发表日期:2024 Sep 30
作者: Ping-Ping Gao, Ling Li, Ting-Ting Chen, Nan Li, Meng-Qi Li, Hui-Juan Zhang, Ya-Ning Chen, Shi-Hao Zhang, Wei Wei, Wu-Yi Sun
来源: ACTA PHARMACOLOGICA SINICA

摘要:

β-arrestin2 是抑制蛋白家族中的关键蛋白,定位于细胞质、质膜和细胞核,调节 G 蛋白偶联受体 (GPCR) 信号传导。最近的证据表明,β-arrestin2 通过介导脱敏和内化,以及充当内化、激酶激活和调节各种信号通路(包括 NF-κB、MAPK 和 TGF)的支架,在调节 GPCR 中发挥双重作用。非 GPCR 的 -β 途径。早期研究已发现β-arrestin2对于调节免疫细胞浸润、炎症因子释放和炎症细胞增殖至关重要。显然,β-arrestin2 是炎症性免疫疾病病理机制中不可或缺的一部分,例如炎症性肠病、脓毒症、哮喘、类风湿性关节炎、器官纤维化和肿瘤。 β-arrestin2 调节的研究为开发针对炎症免疫疾病的药物提供了一种有前景的策略。本综述详细描述了 β-arrestin2 在与炎症免疫反应相关的细胞中的作用,并探讨了其在各种炎症免疫疾病中的病理相关性。© 2024。作者,经中国科学院上海药物研究所独家许可科学与中国药理学会.
β-arrestin2, a pivotal protein within the arrestin family, is localized in the cytoplasm, plasma membrane and nucleus, and regulates G protein-coupled receptors (GPCRs) signaling. Recent evidence shows that β-arrestin2 plays a dual role in regulating GPCRs by mediating desensitization and internalization, and by acting as a scaffold for the internalization, kinase activation, and the modulation of various signaling pathways, including NF-κB, MAPK, and TGF-β pathways of non-GPCRs. Earlier studies have identified that β-arrestin2 is essential in regulating immune cell infiltration, inflammatory factor release, and inflammatory cell proliferation. Evidently, β-arrestin2 is integral to the pathological mechanisms of inflammatory immune diseases, such as inflammatory bowel disease, sepsis, asthma, rheumatoid arthritis, organ fibrosis, and tumors. Research on the modulation of β-arrestin2 offers a promising strategy for the development of pharmaceuticals targeting inflammatory immune diseases. This review meticulously describes the roles of β-arrestin2 in cells associated with inflammatory immune responses and explores its pathological relevance in various inflammatory immune diseases.© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.